These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 9056586)

  • 21. Meta-analysis for bioequivalence review.
    Chow SC; Liu J
    J Biopharm Stat; 1997 Mar; 7(1):97-111. PubMed ID: 9056591
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Generic substitution: the use of medicinal products containing different salts and implications for safety and efficacy.
    Verbeeck RK; Kanfer I; Walker RB
    Eur J Pharm Sci; 2006 May; 28(1-2):1-6. PubMed ID: 16413762
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bioavailability and bioequivalence of topical glucocorticoids.
    Wiedersberg S; Leopold CS; Guy RH
    Eur J Pharm Biopharm; 2008 Mar; 68(3):453-66. PubMed ID: 17826047
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Bioequivalence. An updated reappraisal addressed to applications of interchangeable multi-source pharmaceutical products.
    Marzo A; Balant LP
    Arzneimittelforschung; 1995 Feb; 45(2):109-15. PubMed ID: 7710428
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bridging bioequivalence studies.
    Liu JP
    J Biopharm Stat; 2004 Nov; 14(4):857-67. PubMed ID: 15587968
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Requirements for submission of bioequivalence data; final rule. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2009 Jan; 74(11):2849-62. PubMed ID: 19385107
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Biowaiver: an alternative to in vivo pharmacokinetic bioequivalence studies.
    Mishra V; Gupta U; Jain NK
    Pharmazie; 2010 Mar; 65(3):155-61. PubMed ID: 20383933
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sample size considerations for establishing clinical bioequivalence of allergen formulations.
    Rabin RL; Slater JE; Lachenbruch P; Pastor RW
    Arb Paul Ehrlich Inst Bundesamt Sera Impfstoffe Frankf A M; 2003; (94):24-33. PubMed ID: 15119019
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluation of parametric and nonparametric two one-sided tests procedures for assessing bioequivalence of average bioavailability.
    Liu JP; Weng CS
    J Biopharm Stat; 1993 Mar; 3(1):85-102. PubMed ID: 8485538
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sample size considerations for assessing individual bioequivalence based on the method of tolerance intervals.
    Esinhart JD; Chinchilli VM
    Int J Clin Pharmacol Ther; 1994 Jan; 32(1):26-32. PubMed ID: 8199749
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Alternative confidence intervals for the assessment of bioequivalence in four-period cross-over designs.
    Quiroz J; Ting N; Wei GC; Burdick RK
    Stat Med; 2002 Jul; 21(13):1825-47. PubMed ID: 12111892
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Assessment of bioequivalence using a multiplicative model.
    Chow SC; Peace KE; Shao J
    J Biopharm Stat; 1991; 1(2):193-203. PubMed ID: 1844696
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A modified large sample approach in the assessment of population bioequivalence.
    Quiroz J; Ting N; Wei GC; Burdick RK
    J Biopharm Stat; 2000 Nov; 10(4):527-44. PubMed ID: 11104391
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A log-normal model for individual bioequivalence.
    Phillips KF
    J Biopharm Stat; 1993 Sep; 3(2):185-201. PubMed ID: 8220403
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Assessment of bioequivalence of ciprofloxacin in healthy male subjects using HPLC.
    Khan MK; Khan MF
    Pak J Pharm Sci; 2008 Jul; 21(3):299-306. PubMed ID: 18614429
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Estimating treatment means in a mixed-effect ANOVA model for bioequivalence studies.
    Hsuan FC
    Biometrics; 1993 Sep; 49(3):703-13. PubMed ID: 8241367
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Robustness of bioequivalence procedures under Box-Cox alternatives.
    Xiao W; Barron AM; Liu J
    J Biopharm Stat; 1997 Mar; 7(1):135-55. PubMed ID: 9056594
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Approaching the problem of bioequivalence of herbal medicinal products.
    Loew D; Kaszkin M
    Phytother Res; 2002 Dec; 16(8):705-11. PubMed ID: 12458470
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Plasma pooling: utility in expediting bioequivalence assessment of rifampicin-containing fixed-dose combinations.
    Ashokraj Y; Singh I; Kaur KJ; Kohli G; Bhade SR; Varma MV; Kaul CL; Panchagnula R
    Int J Tuberc Lung Dis; 2005 Jun; 9(6):697-9. PubMed ID: 15971401
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bioequivalence evaluation of 2 different oral formulations of ciprofloxacin in healthy volunteers.
    Galicia I; Frias-Iniesta J; Carcas AJ; Soto A; Gomez E; Miranda E; Fernandez A; Montuenga C
    Int J Clin Pharmacol Ther; 1998 May; 36(5):282-5. PubMed ID: 9629993
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.